Liver biopsy findings and clinical correlates in immune-mediated liver injury from checkpoint inhibitors.

The median age of patients was 62.5 years, 45% received pembrolizumab, and 24% received ipilimumab-nivolumab.

The median latency to liver injury onset was 72 days, and the median time to liver biopsy was 20 days.

Patients biopsied on corticosteroids had significantly less severe inflammation, fewer granulomas, and less cholestasis.

Mild macrovesicular steatosis was common (65%) and associated with diabetes and patient BMI but not corticosteroid use.